J Vet Sci.  2019 Jan;20(1):27-33. 10.4142/jvs.2019.20.1.27.

Development of an oligonucleotide microarray for simultaneous detection of two canine MDR1 genotypes and association between genotypes and chemotherapy side effects

• Lee JJ
• Lin HY
• Chen CA
• Lin CS
• Wang LC

• KMID: 2434774
• DOI: http://doi.org/10.4142/jvs.2019.20.1.27

Abstract

Canine MDR1 gene mutations produce translated P-glycoprotein, an active drug efflux transporter, resulting in dysfunction or over-expression. The 4-base deletion at exon 4 of MDR1 at nucleotide position 230 (nt230[del4]) in exon 4 makes P-glycoprotein lose function, leading to drug accumulation and toxicity. The G allele of the c.-6-180T>G variation in intron 1 of MDR1 (single nucleotide polymorphism [SNP] 180) causes P-glycoprotein over-expression, making epileptic dogs resistant to phenobarbital treatment. Both of these mutations are reported to be common in collies. This study develops a more efficient method to detect these two mutations simultaneously, and clarifies the genotype association with the side effects of chemotherapy. Genotype distribution in Taiwan was also investigated. An oligonucleotide microarray was successfully developed for the detection of both genotypes and was applied to clinical samples. No 4-base deletion mutant allele was detected in dogs in Taiwan. However, the G allele variation of SNP 180 was spread across all dog breeds, not only in collies. The chemotherapy adverse effect percentages of the SNP 180 T/T, T/G, and G/G genotypes were 16.7%, 6.3%, and 0%, respectively. This study describes an efficient way for MDR1 gene mutation detection, clarifying genotype distribution, and the association with chemotherapy.

Keyword

Canine; Chemotherapy; MDR1 gene; Oligonucleotide microarray; P-glycoprotein

MeSH Terms

Alleles
Animals
Dogs
Drug Therapy*
Exons
Genotype*
Introns
Methods
Oligonucleotide Array Sequence Analysis*
P-Glycoprotein
Phenobarbital
Taiwan
P-Glycoprotein
Phenobarbital

Figure

• 

  Fig. 1 Separation of MDR1 genotypes was tested by employing synthesized standard sequences and electrophoresis gels. (A and B) The 4-base deletion genotypes were detected by using 5% agarose gel and 12% polyacrylamide gel electrophoresis gel and 8 h electrophoresis, respectively. Lane M, marker; Lane 1, 4-base no-deletion wild-type genotype (WW genotype); Lane 2, 4-base deletion genotype (MM genotype); Lane 3, hybrid genotype (WM genotype); Lane 4, negative control. (C) The SNP 180 genotypes were detected by using 2% agarose gel and 40-min electrophoresis. Lane M, marker; Lane 1, T/T genotype; Lane 2, G/G genotype; Lane 3, T/G genotype; Lane 4, negative control. (D) Simultaneous detection of the 4-base deletion genotypes and SNP 180 genotypes of MDR1 using multiplex polymerase chain reaction (PCR). Lane M, marker; Lane 1, SNP 180 T/G genotype; Lane 2, 4-base deletion WM genotype; Lane 3, SNP 180 T/G and 4-base deletion WM genotypes; Lane 4, negative control. (E) Lane M, marker; Lanes 1–3, multiplex PCR results from three randomly-selected healthy dogs; Lane 4, negative control. Del 4, a 4-base deletion at exon 4 of the MDR1 gene at nucleotide position 230 (nt230[del4]); SNP, single nucleotide polymorphism.

• 

  Fig. 2 (A) Microarray map. VP1, positive control. The designation of each probe is shown in Table 2. Both the 4-base deletion and SNP 180 genotypes of MDR1 were clearly identified using an oligonucleotide microarray system and either the synthesized standard sequences (B) or clinical dog blood samples (C). WW, WM, and MM indicate wild-type homozygote, heterozygote, and homozygote 4-base deletion mutation genotype of MDR1, respectively. T/T, T/G, and G/G indicate allele-specific genotypes of SNP 180.

• 

  Fig. 3 The relevance of three SNP 180 genotypes to neutrophil number (A), thrombocyte number (B), and hemoglobin concentration (C) in blood from sampled dogs. SNP, single nucleotide polymorphism.

Reference

1. Alves L, Hülsmeyer V, Jaggy A, Fischer A, Leeb T, Drögemüller M. Polymorphisms in the ABCB1 gene in phenobarbital responsive and resistant idiopathic epileptic Border Collies. J Vet Intern Med. 2011; 25:484–489.

2. Baars C, Leeb T, von Klopmann T, Tipold A, Potschka H. Allele-specific polymerase chain reaction diagnostic test for the functional MDR1 polymorphism in dogs. Vet J. 2008; 177:394–397.

3. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013; 123:4131–4133.

4. Bugde P, Biswas R, Merien F, Lu J, Liu DX, Chen M, Zhou S, Li Y. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin Ther Targets. 2017; 21:511–530.

5. Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014; 42:623–631.

6. Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016; 370:153–164.

7. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000; 38:69–74.

8. Geyer J, Döring B, Godoy JR, Moritz A, Petzinger E. Development of a PCR-based diagnostic test detecting a nt230(del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. J Vet Pharmacol Ther. 2005; 28:95–99.

9. Gramer I, Kessler M, Geyer J. Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma. Vet Comp Oncol. 2015; 13:363–372.

10. Kawabata A, Momoi Y, Inoue-Murayama M, Iwasaki T. Canine mdr1 gene mutation in Japan. J Vet Med Sci. 2005; 67:1103–1107.

11. Klintzsch S, Meerkamp K, Döring B, Geyer J. Detection of the nt230[del4] MDR1 mutation in dogs by a fluorogenic 5′ nuclease TaqMan allelic discrimination method. Vet J. 2010; 185:272–277.

12. Lind DL, Fidel JL, Gay JM, Mealey KL. Evaluation of vincristine-associated myelosuppression in Border Collies. Am J Vet Res. 2013; 74:257–261.

13. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001; 11:727–733.

14. Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med. 2015; 29:1–6.

15. Mealey KL, Fidel J, Gay JM, Impellizeri JA, Clifford CA, Bergman PJ. ABCB1-1Δ polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med. 2008; 22:996–1000.

16. Mizukami K, Chang HS, Yabuki A, Kawamichi T, Hossain MA, Rahman MM, Uddin MM, Yamato O. Rapid genotyping assays for the 4-base pair deletion of canine MDR1/ABCB1 gene and low frequency of the mutant allele in Border Collie dogs. J Vet Diagn Invest. 2012; 24:127–134.

17. Mizukami K, Yabuki A, Chang HS, Uddin MM, Rahman MM, Kushida K, Kohyama M, Yamato O. High frequency of a single nucleotide substitution (c.-6-180T>G) of the canine MDR1/ABCB1 gene associated with phenobarbital-resistant idiopathic epilepsy in Border Collie dogs. Dis Markers. 2013; 35:669–672.

18. Plumb DC. Plumb's Veterinary Drug Handbook. Stockholm: PharmaVet;2011.

19. Stiedl CP, Weber K. Fast and simple detection methods for the 4-base pair deletion of canine MDR1/ABCB1 gene by PCR and isothermal amplification. J Vet Diagn Invest. 2017; 29:176–180.

20. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther. 2004; 311:1179–1187.

21. Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 2004; 2:195–213.